Analysis of risk factors for acute cutaneous graft-versus-host disease after allogeneic stem cell transplantation

British Journal of Dermatology

Volumn 148, Issue 6, 2003, Pages 1129-1134

  Vargas Díez, Erich ^a   Fernandez Herrera J ^a   Marin, A ^a   Camara R ^a   Garcia Diez A ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Acute cutaneous graft versus host disease; Allogeneic stem cell transplantation; Risk factors

Indexed keywords

CYCLOSPORIN; METHOTREXATE;

ADULT; AGE; ALLOGRAFT; ARTICLE; BLOOD CELL COUNT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS; DATA BASE; DONOR; FEMALE; GENDER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RECIPIENT; RETROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; SKIN DISEASE; STEM CELL TRANSPLANTATION; SURVIVAL; SURVIVAL RATE; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; FEMALE; GRAFT VS HOST DISEASE; HUMANS; MALE; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTORS; SKIN DISEASES; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0038685075     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05336.x     Document Type: Article

References (23)

1. Horowitz M. Uses and growth of hematopoietic cell transplantation. In: Hematopoietic Cell Transplantation (Thomas E. Blume KG, Forman SJ, eds), 2nd edn. Malden, MA: Blackwell Science, 1999: 12-18.
2. Volc-Platzer B, Stingl G. Cutaneous graft versus host disease. In: Graft-Versus-Host Disease (Ferrara JLM. Deeg HJ. Burakoff SJ, eds). New York: Marcel Dekker, 1997: 245-54.
3. Bross DS, Tutschka J, Farmer ER et al. Predictive factors for acute graft-versus-host disease in patients transplanted with HLA-identical bone marrow. Blood 1984; 63: 1265-70.
4. Gale RP, Bortin MM, van Bekkum DW et al. Risk factors for acute graft-versus-host disease. Br J Haematol 1987; 67: 397-406.
5. Weisdorf D. Hakke R, Blazar B et al. Risk factors for acute-graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991; 51: 1197-203.
6. Nash RA, Pepe MS, Storb R et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838-45.
7. Hägglund H, Bostrom L, Remberger M et al. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 747-53.
8. Kollman C, Howe CWS. Anasetti C et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow unrelated donors: the effect of donor age. Blood 2001; 98: 2043-51.
9. Przepiorka D, Weisdorf D, Martin P et al. Meeting report. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825-8.
10. Morton AJ, Gooley T, Hansen JA et al. Association between pretransplant interferon-α and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92: 394-401.
11. Rodriguez J, Cortes J, Smith T et al. Determinants of prognosis in late chronic-phase chronic myelogenous leukemia. J Clin Oncol 1998; 16: 3782-7.
12. Tomas JF, Lopez-Lorenzo JL, Requena MJ et al. Absence of influence of prior treatment with interferon on the outcome of allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1998; 22: 47-51.
13. Zuffa E, Bandini G, Bonini A et al. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia. Haematologica 1998; 83: 231-6.
14. Lee SJ, Klein JP, Anasetti C et al. The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietoic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase. Blood 2001; 98: 3205-11.
15. Holler E, Ferrara JLM. Antagonists of inflammatory cytokines: prophylactic and therapeutic applications. In: Graft-Versus-Host Disease (Ferrara JLM, Deer HJ, Burakoff SJ, eds). New York: Marcel Dekker, 1997: 667.
16. Hill GR, Crawford JM, Cooke KR et al. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood 1997; 90: 3204-13.
17. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867-71.
18. Hartman AR, Williams SF, Dillon JJ. Survival, disease-free survival and adverse effects of conditioning for allogeneic bone marrow transplantation with busulfan/cyclophosphamide vs total body irradiation: a meta-analysis. Bone Marrow Transplant 1998; 22: 439-43.
19. Bosi A, Laszlo D, Labopin M et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675-84.
20. Radich J, Sanders J, Buckner C et al. Second allogeneic bone marrow transplantation for patients with recurrent leukemia after initial transplant with total-body-irradiation-containing regimens. J Clin Oncol 1993; 11: 304-13.
21. Michallet M. Tanguy ML, Socie G et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle (SFGM). Br J Haematol 2000; 10: 8400-7.
22. Frassoni F, Barret A, Granena A et al. Relapse after allogeneic bone marrow transplantation for acute leukemia: a survey by the EBMT of 117 cases. Br J Haematol 1988; 70: 317-20.
23. Kumar L. Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 1994; 7: 50-7.